1,5-disubstituted 1,2,3-triazoles are inhibitors of RAC/CDC42 GTPases
AssigneeUniversity of Puerto Rico
InventorsCornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Eliud Hernandez-O'farrill, Linette Castillo-Pichardo
Life of this patent
Estimating the term…
Abstract
Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.
Claims20
A compound of formula
A pharmaceutical composition comprising a compound of formula
A method of treating cancer in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of formula
- wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, ovarian cancer, gastric cancer, and neuronal cancer.
Dependencies are inferred from the claim text.